38 Amendments of Jean-François JALKH related to 2017/2254(INI)
Amendment 15 #
Motion for a resolution
Recital A
Recital A
A. whereas the excessive and inappropriate use of antibiotics, or substances that can potentiate the undesirable effects of antibiotics on human and animal health and in livestock farms, and poor infection control practices have progressively rendered antimicrobial resistance (AMR) a massive threat to humankind;
Amendment 27 #
Motion for a resolution
Recital A a (new)
Recital A a (new)
Aa. whereas excessive use of antiseptics depletes healthy bacteria populations, the first defence against antibiotic-resistant bacteria;
Amendment 32 #
Motion for a resolution
Recital A b (new)
Recital A b (new)
Ab. whereas phytosanitary products used on a massive scale, such as glyphosate, have antimicrobial side- effects whose impact has not yet been fully evaluated;
Amendment 33 #
Motion for a resolution
Recital A c (new)
Recital A c (new)
Ac. whereas alternative therapies, such as phage therapy, are available and are in development;
Amendment 55 #
Motion for a resolution
Recital D a (new)
Recital D a (new)
Da. whereas antimicrobial resistance is just as transmissible as the infections concerned;
Amendment 57 #
Motion for a resolution
Recital E
Recital E
E. whereas the World Bank in its abovementioned report has warned that by 2050, drug-resistant infections could cause global economic damage on a par with the 2008 financial crisis, and that two new phenomena are making the situation worse: the current very intensive manufacture of active substances for antibiotics in China and India, which puts the Member States at risk of economic and sanitary dependence; the recent mass influx into Europe of migrants carrying multidrug-resistant tuberculosis and serious illnesses which would otherwise be mild in Europe;
Amendment 86 #
Motion for a resolution
Paragraph 1
Paragraph 1
1. Believes that in order to take sufficient steps to tackle AMR, the One Health principle must play a central role, reflecting the fact that the health of people and animals are interconnected and that diseases are transmitted from people to animals and vice versa; stresses, therefore, that diseases have to be tackled in both people and animals, while also taking into consideration the environment and agricultural practices, which can be another source of resistant microorganisms;
Amendment 94 #
Motion for a resolution
Paragraph 1 a (new)
Paragraph 1 a (new)
1a. Calls, for that reason, for possible primary and secondary antimicrobial effects to be included in the evaluation of phytosanitary products and chemical products in general;
Amendment 104 #
Motion for a resolution
Paragraph 2
Paragraph 2
2. Stresses that the appropriate and prudent use of antimicrobials is essential to limiting the emergence of AMR in human healthcare, animal husbandry and aquaculture; stresses that there are considerable differences in the way Member States handle and address AMR; highlights the success of national campaigns educating citizens on good antibiotic practices and praises the Member States who have taken the matter seriously; calls on the Commission to consider mandatory routine collection and submission of monitoring data at EU level and to establish indictors to measure progress in the fight against AMR;
Amendment 132 #
Motion for a resolution
Paragraph 3
Paragraph 3
3. Calls onUrges the Commission and the Member States to align surveillance, monitoring and reporting of AMR patterns and pathogens by means of ongoing cooperation between scientists;
Amendment 150 #
Motion for a resolution
Paragraph 4
Paragraph 4
4. Calls on the Commission to develop standardised surveys for collecting specific data on HAIs;
Amendment 175 #
Motion for a resolution
Paragraph 6 a (new)
Paragraph 6 a (new)
6a. Stresses the need for maximum prevention in hospitals, which are hotbeds for contamination by antibiotics-resistant microorganisms;
Amendment 182 #
Motion for a resolution
Paragraph 7
Paragraph 7
7. Calls on the Commission and the Member States to develop public health messages to raise public awareness and in doing so promote a change in behaviour towards the use of antibiotics, with regard not only to consumption but also to waste management; underlines the importance of promoting ‘health literacy’, since it is crucial that patients understand healthcare information and are able to follow treatment instructions accurately;
Amendment 201 #
Motion for a resolution
Paragraph 8 a (new)
Paragraph 8 a (new)
8a. Encourages the Member States to improve initial and continuous training for prescribing doctors and veterinarians;
Amendment 202 #
Motion for a resolution
Paragraph 8 b (new)
Paragraph 8 b (new)
8b. Stresses that giving out antimicrobial treatments strictly for the length of treatments only could reduce public healthcare costs and prevent overconsumption of antibiotics, particularly self-medication;
Amendment 209 #
Motion for a resolution
Paragraph 9
Paragraph 9
9. Is aware that health professionals often need to make quick decisions on therapeutic indication for antibiotic treatment; notes that rapid diagnostic tests can help to support these decisions and calls for incentive systems to be put in place to promote their use;
Amendment 212 #
Motion for a resolution
Paragraph 10
Paragraph 10
10. Is aware that the cost of rapid diagnostic tools (RDT) may exceed the price of antibiotics; calls on the CommissionMember States to propose incentives for the industry to develop effective and efficient testing methods and calls on health insurance carriers to coverestimate the extra cost arising from the use of RDT, given from the perspective of the long-term benefits of preventing the unnecessary use of antimicrobials;
Amendment 229 #
Motion for a resolution
Paragraph 11
Paragraph 11
11. Calls on the Commission and the Member States to restrict or stop the sale of antibiotics, by those doctors or veterinarians who prescribe them, only to areas where there are pharmacies; points out that preventing the selling of antimicrobials by veterinarians is not the solution for significantly reducing sales thereof;
Amendment 259 #
Motion for a resolution
Paragraph 12
Paragraph 12
12. Highlights the value of some vaccines in combating AMR; recommends integration of targets for life-long vaccination as a key element of national action plans on AMR;
Amendment 265 #
Motion for a resolution
Paragraph 12 a (new)
Paragraph 12 a (new)
12a. Stresses also how dangerous late forms of some diseases are where vaccination has been unsupervised;
Amendment 277 #
Motion for a resolution
Paragraph 13 a (new)
Paragraph 13 a (new)
13a. Points out that natural water filtration may take nearly 70 years, making it impossible to measure the real environmental impact of mass consumption of antibiotics over the last few decades;
Amendment 284 #
Motion for a resolution
Paragraph 13 b (new)
Paragraph 13 b (new)
13b. Calls on the Member States to introduce incentive schemes for collecting unused antibiotics;
Amendment 286 #
Motion for a resolution
Paragraph 13 c (new)
Paragraph 13 c (new)
13c. Is concerned at what is now the very intensive production of active substances for antibiotics in China and India, posing an unassessable risk of environmental pollution in very densely populated areas with high volumes of international comemrcial traffic;
Amendment 292 #
Motion for a resolution
Paragraph 14
Paragraph 14
14. Calls for environmental risk assessments as part of the marketing authorisation process for antimicrobials on the basis of type or purpose;
Amendment 323 #
Motion for a resolution
Paragraph 15 a (new)
Paragraph 15 a (new)
15a. Urges the Commission to grant funding for research projects on new treatments, and regards the issue as sufficiently serious and strategic to warrant EFSI funding, in particular in connection with micropollutants with antimicrobial secondary effects;
Amendment 325 #
Motion for a resolution
Paragraph 15 b (new)
Paragraph 15 b (new)
15b. Calls on the EU and the Member States to do their utmost to relocate research and development and the production of active substances for antibiotics within the EU, as a matter of urgency, where production outside the EU is quasi-monopolistic and poses health dependence risks for the Member States;
Amendment 331 #
Motion for a resolution
Paragraph 16 a (new)
Paragraph 16 a (new)
16a. Stresses the high expectations and efforts of start-ups working on phage therapy and calls for procedures for authorising the placing on the market of new technologies to be facilitated, with a view to adding to the current battery of treatments;
Amendment 332 #
Motion for a resolution
Paragraph 16 b (new)
Paragraph 16 b (new)
16b. Calls on European and national authorities to approach health authorities elsewhere in the world, including in Russia, which have long been using bacteriophage therapy in order to obtain feedback;
Amendment 334 #
Motion for a resolution
Paragraph 17
Paragraph 17
17. Encourages the European Medicines Agency (EMA) to review all available information on the benefits and risks of older antimicrobial agents and to consider whether any changes to their approved uses are required; calls on the EFSA and EMA to look immediately into the antimicrobial effects of glyphosate and other substances and their environmental and health implications;
Amendment 381 #
Motion for a resolution
Paragraph 22
Paragraph 22
22. Notes the hesitant approach of the industry to develop ‘last-line’ antibiotics against bacteria that are resistant to all other antibiotics owing to expected low profitability; calls for incentives for this research and definition of the regulatory pathwayon the Member States to create incentives for this research;
Amendment 385 #
Motion for a resolution
Paragraph 23
Paragraph 23
23. Calls on the Commission and the Member States to develop new incentive models that delink payment from prescribing volumeexamine the good practices of Member States that have managed to reduce antibiotic use significantly without resorting to delinking, but rather by fully integrating veterinarians into the public health approach and recognising their role as guardians of health;
Amendment 417 #
Motion for a resolution
Paragraph 26
Paragraph 26
26. Notes that AMR is of serious concern in many poverty-related and neglected diseases (PRNDs) and diseases linked to migration, including HIV/AIDS, malaria and tuberculosis (TB); highlights that about 29 % of deaths caused by AMR are due to drug-resistant TB, and calls on the Commission and the Member States to increase their support to research for health tools to address PRNDs affected by AMR;
Amendment 420 #
Motion for a resolution
Paragraph 26 a (new)
Paragraph 26 a (new)
26a. Stresses that these diseases are back in Europe for two main reasons: the current budgetary policies, which are increasing levels of poverty, and migration policies; points out that the migrants who have already reached Europe and who are suffering from multidrug-resistant tuberculosis should be taken into care to limit the risk of contagion;
Amendment 422 #
Motion for a resolution
Paragraph 26 b (new)
Paragraph 26 b (new)
26b. Stresses that a migration and development policy involving the treatment of sick people in their country of origin would be far more responsible than letting sick migrants enter the EU;
Amendment 424 #
Motion for a resolution
Paragraph 26 c (new)
Paragraph 26 c (new)
26c. Deplores the fact that the tuberculosis vaccine was struck off the list of mandatory vaccines in the EU a very long time ago in favour of unnecessary vaccines, and that international anti- tuberculosis programmes have failed to achieve results;
Amendment 425 #
Motion for a resolution
Paragraph 26 d (new)
Paragraph 26 d (new)
6d. Expresses concern at the importation of hyper-hygienic habits that are promoting the spread of saprophytic bacteria that are themselves resistant to antibiotics;
Amendment 426 #
Motion for a resolution
Paragraph 27
Paragraph 27
Amendment 433 #
Motion for a resolution
Paragraph 27 a (new)
Paragraph 27 a (new)
27a. Expresses indignation at the potential signing of trade agreements with countries that authorise the use of antibiotics as animal growth factors or which do not have a responsible policy for the control of antibiotic prescriptions, thus exposing Europeans, via imports, to the very dangers that this report is trying to limit;